Ireland · Delayed Price · Currency is EUR Uniphar Earnings Call Transcripts
Fiscal Year 2025
-
Strong organic growth across all divisions drove a 21% EPS increase and 6% EBITDA growth in 2025, supported by major infrastructure investments and disciplined capital allocation. The group remains confident in achieving its EUR 200 million EBITDA target by 2028.
-
Strong H1 2025 results with 8% organic gross profit growth and 21% EPS increase, driven by all divisions. Strategic investments in infrastructure and technology are expected to support medium-term EBITDA growth, with a €200m target by 2028.
Fiscal Year 2024
-
Strong 2024 results with 9.6% gross profit growth and 12% EPS increase, driven by all divisions. Strategic investments and disciplined capital allocation support a €200 million EBITDA target by 2028, with robust organic growth and market share gains in Pharma and MedTech.
-
Revenue and gross profit both grew 10% year-over-year, with Pharma leading at 21% gross profit growth. EBITDA rose 6%, leverage improved, and strong organic growth was achieved across all divisions. The group remains confident in its ambitious €200m EBITDA target.